All News

Found 297 articles

• Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease

  2/24/2023

  Fulcrum Therapeutics, Inc.® (Nasdaq: FULC) today announced that on February 23, 2023, the U.S. Food and Drug Administration (FDA) verbally informed the company that it has issued a full clinical hold regarding the Investigational New Drug (IND) application for FTX-6058 for the potential treatment of sickle-cell disease.

• Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 10, 2023

  2/10/2023

  Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees.

• Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference

  2/8/2023

  Fulcrum Therapeutics, Inc.® (Nasdaq: FULC) today announced that management will participate in a virtual presentation at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 AM ET.

• Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock - Jan 18, 2023

  1/18/2023

  Fulcrum Therapeutics, Inc. announced the pricing of an underwritten public offering of 9,615,384 shares of its common stock at a public offering price of $13.00 per share.

• Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock - Jan 17, 2023

  1/17/2023

  Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock.

• Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 13, 2023

  1/13/2023

  Fulcrum Therapeutics, Inc. announced that the Company granted non-statutory stock options to new employees.

• Fulcrum Therapeutics Announces CEO Transition - Jan 04, 2023

  1/4/2023

  Fulcrum Therapeutics, Inc.® announced that Robert J. Gould, Ph.D., former founding chief executive officer of Fulcrum and a current member of the Board of Directors, has been appointed interim chief executive officer, effective January 3, 2023.

• Fulcrum Therapeutics Provides Business Update and 2023 Outlook

  1/4/2023

  Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today outlined its recent accomplishments and expected 2023 milestones.

• Brain Scientific Signs Agreement with MVAP Medical Supplies to Go After Rapidly Growing Pediatric Neurodiagnostic Space

  12/15/2022

  Brain Scientific, a Florida-based applied science technology company, announces a new distribution agreement with MVAP Medical Supplies to drive sales into the rapidly growing and underserved pediatric EEG marketplace.

• Verge Genomics Appoints Diego Cadavid, M.D., as Chief Medical Officer

  12/6/2022

  Verge Genomics announced today that it appointed Diego Cadavid, M.D., as its first Chief Medical Officer.

• ONK Therapeutics Boosts Drug Development Experience and Expands US Presence with the Appointment of Bruce McCreedy Ph.D. as Chief Scientific Officer

  12/6/2022

  ONK Therapeutics, an innovative company dedicated to developing optimally engineered natural killer cell therapies to cure patients with cancer, announced the appointment of Bruce McCreedy Ph.D. as Chief Scientific Officer.

• Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 05, 2022

  12/5/2022

  Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that the Company granted non-statutory stock options to new employees.

• Brain Scientific Inks Deal with Fulcrum to Go After At-Home Diagnostic Space, Hires VP of Marketing and Communications

  12/1/2022

  Brain Scientific, a Florida-based applied science technology company, announces a new distribution agreement with Fulcrum to drive sales, and the company further announces the hiring of Kevin Winterfield as vice president of marketing and communications to accelerate Brain Scientific’s strategic growth plan heading into the new year.

• Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference

  12/1/2022

  Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a virtual fireside chat at the 2022 BofA Securities Biotech SMID Cap Conference, on Thursday, December 8, 2022 at 9:10 a.m. ET

• Advantum Health Announces New Executive Leadership Appointments

  11/16/2022

  Advantum Health, an industry-leading practice revenue management authority, announced the appointment of Tammy Taylor as Chief Executive Officer and Chris Taft as Chief Financial Officer.

• Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 11, 2022

  11/11/2022

  Fulcrum Therapeutics, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company’s 2019 Stock Incentive Plan.

• Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results

  11/8/2022

  Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today reported financial results for the third quarter of 2022.

• Asensus Surgical Announces Ludwig Maximilians University in Germany to Initiate Senhance Pediatric Surgery Program

  11/8/2022

  Asensus Surgical, Inc. today announced that the Dr. von Hauner Children’s Hospital at the Ludwig Maximilians University Munich (“LMU”), has entered into an agreement to lease and utilize a Senhance® Surgical System.

• Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer

  11/7/2022

  Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Medical Officer, and Jeff W. Jacobs, Ph.D., as Chief Scientific Officer.

• Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET

  11/2/2022

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that its third quarter 2022 financial results will be released on Tuesday, November 8, 2022 before the U.S. financial markets open.